Participants on weekly injections of 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks, and 45.3% of participants achieved ≥ 30% weight loss.

Over half of patients in a randomized trial switch from enzalutamide to darolutamide because of cognitive issues; no one switches in the opposite direction.

Analysis of data from the PUSH randomized trial affirmed that more fluid increase is better, but some still helps.

Biopsy and next-generation sequencing identified an HSV 1 variant causing ulcerative esophagitis and ileitis in a healthy 26 ...

An analysis conducted in an integrated healthcare system provided insights into the long-term healthcare burden of cCMV ...

A new study finds that prior authorization requirements vary widely across major insurers and suggests large language models ...

Creatinine muscle index can serve as a blood biomarker to estimate low muscle mass and identify individuals at an increased ...

The FDA’s recent approval of baxdrostat may usher in new possibilities for treatment for uncontrolled hypertension.

Experts say biomarker research and multiomics are pushing rheumatology toward more individualized treatment strategies and earlier disease classification.

Health leaders in Spain debate balancing maternal-fetal safety with respectful, informed care, spotlighting birth plans, ...

Rapid microbiological point-of-care testing for respiratory tract infections does not reduce overall same-day antibiotic prescribing in primary care, a recent study shows.

Nutrition science is closing in on truly personalized dietary advice. The bigger challenge? Making sure it does not only land ...